Despite Johnson & Johnson reporting better-than-expected Q1 2025 adjusted EPS of $2.77 and revenue of $21.9 billion, shares fell marginally on Apr. 15 due to concerns over declining Stelara sales ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...

Despite Johnson & Johnson's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Johnson & Johnson (NYSE: JNJ) is an iconic U.S. healthcare giant. There are a lot of positives with J&J, as it is more ...

US stocks on the S&P 500, Nasdaq and Dow rose as job data exceeded market expectations amid Trump tariff concerns. Job data ...

Johnson & Johnson reported third-quarter results before the stock market opened on Tuesday, Oct. 15. Johnson & Johnson raised its sales outlook but lowered its guidance range for adjusted earnings.

Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance Provided by Dow Jones Jan 22, 2025, 4:45:00 PM. By Ciara Linnane .

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ... up 2.5% on the previous year but below Wall Street estimates of $8. ...

I covered the company at the Wall Street Journal, at the New York Times. For tough stories, Johnson & Johnson has historically refused to participate in any of these stories.

Although Johnson & Johnson has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year.

Earnings Results Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance Medical-technology and drug company’s 2025 sales outlook is below consensus ...